Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib vs BAT in Ruxolitinib-Treated Myelofibrosis
NCT02101268Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by GSK. Primary endpoint: Splenic Response Rate at Week 24. Started Jun 2014; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT02101268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101268.